Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study
Tiagabine increases cocaine-free urines in cocaine-dependent methadone-treated patients: results of a randomized pilot study
复制标题
DOI：
10.1046/j.1360-0443.2003.00544.x
复制
发表时间：
2003-11-01
期刊：
影响因子：
6
通讯作者：
Kosten, TR
中科院分区：
文献类型：
--
作者：
Gonzalez, G;Sevarino, K;Kosten, TR
目的我们试图评估GABA能药物噻加宾在减少美沙酮治疗患者中可卡因使用的安全性和有效性。设计10周随机双盲安慰剂对照试验。设置阿片治疗研究项目，退伍军人事务部康涅狄格州医疗保健系统在美国康涅狄格州西黑文。参与者参与者是45名可卡因依赖性美沙酮治疗患者，主要是白人（75.6%），男性（77.8%）和从未结婚（53%），平均年龄为38岁（SD = 6.5）。干预比较组接受噻加滨12 mg/天（n = 15），噻加滨24 mg/天（n = 15）或安慰剂（n = 15）。成瘾严重程度指数，尿液药物测试，自我报告的使用和阿片类药物戒断量表。尿液药物检测每周进行三次。结果治疗保留率超过80%，所有治疗组。入组研究后第一周和开始噻加滨治疗前的无可卡因尿液样本平均值（+/-SE）为1.16（0.19）次尿液/周。在第9周和第10周期间，高剂量噻加滨（24 mg/天）组的无可卡因尿液较基线显著增加33%，低剂量噻加滨（12 mg/天）组增加14%，安慰剂组减少10%（分层线性模型，Z = 2.03; P < 0.05）。自我报告的可卡因使用也减少了显着更多的活性药物比placebo.Conclusions噻加宾在24毫克/天，这些美沙酮治疗的患者只有一个报告头痛的耐受性良好。噻加宾似乎是一种有前途的GABA能药物，可适度改善无可卡因尿。
Aims We sought to evaluate the safety and efficacy of the GABAergic agent tiagabine in reducing cocaine use among methadone-treated patients.Design Ten-week randomized double-blind placebo-controlled trial.Setting Opiate Treatment Research Program, Veteran's Affairs Connecticut Healthcare System in West Haven Connecticut USA.Participants The participants were 45 cocaine-dependent meth a done-treated patients who were predominately Caucasian (75.6%), male (77.8%) and never married (53%) with an average age of 38 years (SD = 6.5).Interventions Comparison groups received tiagabine 12 mg/day (n = 15), tiagabine 24 mg/day (n = 15) or placebo (n = 15).Measures Baseline assessments included the Structured Clinical Interview for DSM-IV. the Addiction Severity Index, a urine drug test, self-reported use and opiate withdrawal scales. Urine drug tests were performed thrice weekly.Findings Treatment retention was over 80%, for all treatment groups. The sample mean (+/-SE) of cocaine-free urines for the first week after study entry and before tiagabine was started was 1.16 (0.19) urines/week. During weeks 9 and 10 cocaine-free urines increased significantly from baseline by 33% with high-dose tiagabine (24 mg/day), by 14%, with low-dose tiagabine (12 mg/day) and decreased by 10% with placebo (hierarchical linear model, Z = 2.03; P < 0.05). Self-reported cocaine use also decreased significantly more with active medications than with placebo.Conclusions Tiagabine at 24 mg/day was well tolerated among these methadone-treated patients with only one reporting headache. Tiagabine appears to be a promising GABAergic medication that moderately improves cocaine-free urines.